Novavax NVAX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $139.51M-5.2% | $147.14M+109% | $70.45M-70.6% | $239.24M-64.1% | $666.66M+655% | ||
| $30.7M+38.9% | $22.1M+2.8% | $21.5M+40.3% | $15.33M+8.6% | $14.12M-61.5% | ||
| $108.82M-13.0% | $125.04M+155% | $48.95M-78.1% | $223.92M-65.7% | $652.54M+1,164% | ||
| 78%-7.0pp | 85%+15.5pp | 69.5%-24.1pp | 93.6%-4.3pp | 97.9%+39.4pp | ||
| $95.47M+25.8% | $75.88M-22.8% | $98.27M+24.0% | $79.23M-10.9% | $88.94M-14.8% | ||
| $28.78M-15.7% | $34.12M+7.8% | $31.66M-27.4% | $43.61M-9.3% | $48.09M-38.6% | ||
| $154.94M+16.6% | $132.91M-46.5% | $248.46M+79.8% | $138.17M-8.6% | $151.14M-31.1% | ||
| -$15.43M-208% | $14.23M+108% | -$178.02M-276% | $101.07M-80.4% | $515.51M+493% | ||
| -11.1%-20.7pp | 9.7%+262pp | -252.7%-295pp | 42.2%-35.1pp | 77.3%+226pp | ||
| $4.9M-15.8% | $5.82M+6.2% | $5.48M-0.7% | $5.52M-3.6% | $5.72M-24.5% | ||
| $11.83M+24.5% | $9.5M+3.5% | $9.18M-22.9% | $11.9M+18.4% | $10.06M-23.4% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$8.51M-148% | $17.9M+109% | -$203.04M-289% | $107.45M-79.3% | $519.85M+806% | ||
| $985K+162% | $376K+157% | -$657K-169% | $946K-21.2% | $1.2M-83.9% | ||
| -$9.49M-154% | $17.53M+109% | -$202.38M-290% | $106.51M-79.5% | $518.65M+740% | ||
| -6.8%-18.7pp | 11.9%+299pp | -287.3%-332pp | 44.5%-33.3pp | 77.8%+170pp | ||
| -$0.06-220% | $0.05+104% | -$1.25-302% | $0.62-78.8% | $2.93+663% | ||
| -$0.06-155% | $0.11+109% | -$1.25-289% | $0.66-79.5% | $3.22+719% | ||
| 163.3M-5.7% | 173.1M+6.6% | 162.4M-8.4% | 177.2M-0.2% | 177.6M+16.7% | ||
| 163.3M+0.8% | 162M-0.2% | 162.4M+0.2% | 162M+0.6% | 161M+5.8% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $11.83M+24.5% | $9.5M+3.5% | $9.18M-22.9% | $11.9M+18.4% | $10.06M-23.4% | ||
| -$15.43M-208% | $14.23M+108% | -$178.02M-276% | $101.07M-80.4% | $515.51M+493% | ||
| -$12.37M-164% | $19.36M+111% | -$171.43M-258% | $108.63M-79.3% | $523.85M+542% | ||
| -$12.37M-164% | $19.36M+111% | -$171.43M-258% | $108.63M-79.3% | $523.85M+542% | ||
| -8.9%-22.0pp | 13.2%+257pp | -243.4%-289pp | 45.4%-33.2pp | 78.6%+213pp | ||
| -$15.43M-208% | $14.23M+108% | -$178.02M-276% | $101.07M-80.4% | $515.51M+493% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Novavax's revenue?
- Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.
- Is Novavax profitable?
- Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.
- What are Novavax's profit margins?
- Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.
- What is Novavax's earnings per share?
- Novavax's diluted EPS over the trailing twelve months is $-0.64.
- Where does Novavax's income statement data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
